Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derivedneurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD). Methods: Major depressive episode was diagnosed using the Structured Clinical Interview for the Diagnostic and StatisticalManual of Mental Disorders-fourth edition (DSM-IV) according to the DSM-IV text revision (DSM-IV-TR) criteria. The severityof depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Blood sampling and clinicalevaluation were performed on days 0, 28, and 56. Results: Duloxetine treatment for 8 weeks significantly increased the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levelsbut not the homovanillic acid (HVA) levels in responders with MDD. Conclusion: These results imply that noradrenaline plays an important role in alleviating depressive symptoms.
Abstract
Objective: We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derivedneurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD). Methods: Major depressive episode was diagnosed using the Structured Clinical Interview for the Diagnostic and StatisticalManual of Mental Disorders-fourth edition (DSM-IV) according to the DSM-IV text revision (DSM-IV-TR) criteria. The severityof depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Blood sampling and clinicalevaluation were performed on days 0, 28, and 56. Results: Duloxetine treatment for 8 weeks significantly increased the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levelsbut not the homovanillic acid (HVA) levels in responders with MDD. Conclusion: These results imply that noradrenaline plays an important role in alleviating depressive symptoms.
참고문헌 (8)
- Pergolizzi JV Jr, "A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain", Pain Pract, 13, pp.239~252 (2013)
- Shinkai K, "Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment", J Clin Psychopharmacol, 24, pp.11~17 (2004)
- Yoshimura R, "Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1034~1037 (2007)
- Sen S, "Serum brain-derived neurotrophic factor, depression, and antidepressant medications:meta-analyses and implications", Biol Psychiatry, 64, pp.527~532 (2008)
- Bocchio-Chiavetto L, "Serum and plasma BDNF levels in major depression: a replication study and metaanalyses", World J Biol Psychiatry, 11, pp.763~773 (2010)
- Fernandes BS, "Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis", J Psychiatr Res, 45, pp.995~1004 (2011)
- Katsuki A, "Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)", CNS Spectr, 17, pp.155~163 (2012)
- Chalon SA, "Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study", Neuropsychopharmacology, 28, pp.1685~1693 (2003)